Drugs / ANA
last change Sep 2026 re-read 9 days ago

ANA

Developed for
essential thrombocythemia
Investigated by
Incyte Corporation

Trials 1

202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07623200 Sep 2026 → Jun 2029 expected essential thrombocythemia Incyte Corporation Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ANA “• ANA” NCT07623200 ↗